while there was no significant difference between the low-risk group and the wild-type group (p ¼ 0.695, figure 1c). Moreover, when we combined the groups into a high-risk/truncating group and a low-risk/ wild-type group, the high-risk/truncating group had a significantly worse recurrence-free survival (p ¼ 0.0081, figure 3c) and overall survival (p ¼ 0.0029, figure 1c). Conclusion: TP53 mutational type is of prognostic value for patients with stage I lung adenocarcinoma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.